Guardant Health, Inc. (GH)
| Market Cap | 16.33B |
| Revenue (ttm) | 271.31M |
| Net Income (ttm) | -185.25M |
| Shares Out | 99.55M |
| EPS (ttm) | -1.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $161.64 |
| Previous Close | $163.34 |
| Change ($) | -1.71 |
| Change (%) | -1.04% |
| Day's Open | 164.00 |
| Day's Range | 159.55 - 164.93 |
| Day's Volume | 361,808 |
| 52-Week Range | 59.04 - 164.93 |
BARCELONA, Spain & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Vall d'Hebron Institute of Oncology (VHIO), one of Europ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, will present data highlighting the clinical ut...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 39th Annual J...
As is the case every year, the major Wall Street firms we cover here at 24/7 Wall St.
All three could be huge winners in the new year -- and over the long run.
All three have already made investors a lot of money this year.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has named Michael Bell as the company's new Chief Financial Officer (CFO) effec...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, shares new data at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS)...
All three are already big winners this year. Even better days could be in store.
As COVID-19 decelerates its growth, Guardant has failed to generate sizable capital gains despite the recent FDA signoff. With vaccine hopes rising, the consensus revenue estimates look overly...
Multiple companies are working on next-gen blood biopsies tech to detect cancer. The potential market size is big according to most estimates and analysts.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) today announced the pricing of its offering of $1,000,000,000 aggregate principal amount of 0% convertible senior note...
Hint: The diagnostics company's balance sheet is going to record some big changes quite soon.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) today announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amo...
These two diagnostics companies are trying to cash in on demand for coronavirus tests.
Guardant Health, Inc. (GH) CEO Helmy Eltoukhy on Q3 2020 Results - Earnings Call Transcript
Guardant Health (GH) delivered earnings and revenue surprises of -129.41% and 12.18%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the s...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood ...
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Big Tech companies have been the hottest stocks on Wall Street all year, pre- and post-pandemic. But some experts think it's time for a new crop of dynamic up-and-comers in fields like virtual...
The company is chasing a massive opportunity, but growth slowed this year.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the third quarter 2020 after market close on Thursday, November 5...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of it...
Disruptive companies with a smaller market cap can be a key component to achieving a seven-figure nest egg.
These companies are likely to be a lot bigger in 2040 -- and make patient investors a ton of money along the way.
Softbank is offering shares of the precision oncology company at a (temporary) bargain price.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of it...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of it...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH). Despite advances in precision oncology, progress is slowed by the limitations of tissue genotyping, which is traditio...
COVID-19 has created an Apollo Mission status for advanced medical technologies and smart investors are profiting.
Bullish charts across the healthcare services subsector suggest that this niche segment could be the one to watch over the months ahead.
This company's diagnostic blood tests made it a hot IPO two years ago, but competitors are catching up, and COVID-19 could derail its critical study.
They're all innovative disruptors, but these three stocks could outperform Tesla over the next decade.
Sure, Tesla stock has been on fire this year. But these three stocks could be bigger winners over the long run.
REDWOOD CITY, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcar...
Sometimes the best place to look for a stock that could double is checking out the ones that already have.
Intuitive Surgical, Edwards Lifesciences, Boston Scientific, Novocure and Guardant Health are top medical stocks that may thrive as coronavirus cases fall.
You don't need a huge initial investment with massive growth opportunities from these stocks.
If you won't need that $1,200 to pay your immediate bills, why not use it to bolster your long-term financial plan?
Guardant Health on Monday announced that the U.S. Food and Drug Administration granted emergency use authorization for its Covid-19 test.
COVID-19 diagnostic expands testing supply, protects the continuity of essential cancer work at Guardant Health, and helps with reopening at Delaware State University COVID-19 diagnostic expan...
REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the following investor virtual conferences.
Guardant Health, Inc. (GH) CEO Helmy Eltoukhy on Q2 2020 - Earnings Call Transcript
SINGAPORE, Aug. 7, 2020 /PRNewswire/ -- The U.S.
Now FDA approved, the Guardant360 CDx delivers critical genomic information to oncologists from a simple blood draw Now FDA approved, the Guardant360 CDx delivers critical genomic information ...
The liquid biopsy company beat revenue estimates in Q2, but its bottom line fell short of expectations.
Guardant Health (GH) delivered earnings and revenue surprises of -42.50% and 10.86%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Q2 2020 Revenue Increase of 23% Over Prior Year Period
About GH
Guardant Health, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer su... [Read more...]
| Industry Diagnostics & Research | IPO Date Oct 4, 2018 |
| Stock Exchange NASDAQ | Ticker Symbol GH |
Financial Performance
In 2019, GH's revenue was $214.38 million, an increase of 136.52% compared to the previous year's $90.64 million. Losses were -$75.65 million, -11.06% less than in 2018.
Analyst Forecasts
According to 11 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price forecast is 151.89, which is a decrease of -6.03% from the latest price.